TaiMed Biologics Inc. (TPEX:4147)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
48.05
-0.25 (-0.52%)
Apr 28, 2026, 1:30 PM CST
-39.94%
Market Cap 13.20B
Revenue (ttm) 611.35M
Net Income (ttm) -167.78M
Shares Out 273.20M
EPS (ttm) -0.61
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 459,403
Average Volume 1,131,342
Open 48.30
Previous Close 48.30
Day's Range 47.75 - 48.30
52-Week Range 47.50 - 98.50
Beta -0.12
RSI 34.96
Earnings Date May 11, 2026

About TaiMed Biologics

TaiMed Biologics Inc., a biotechnology company, develops, manufactures, and commercializes drugs for the treatment and prevention of infectious diseases. The company develops and markets Trogarzo IV infusion and Trogarzo IV push, a monoclonal antibody for HIV treatment. It is also developing TMB-365, a monoclonal antibody used for HIV treatment and prevention which has completed a phase-1 clinical trial; and TMB-365 and TMB-380 combination, a monoclonal antibody combination therapy for HIV that is in phase-1b/2a clinical trial, as well as antib... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2007
Country Taiwan
Stock Exchange Taipei Exchange
Ticker Symbol 4147
Full Company Profile

Financial Performance

In 2025, TaiMed Biologics's revenue was 611.35 million, an increase of 0.19% compared to the previous year's 610.16 million. Losses were -167.78 million, -16.87% less than in 2024.

Financial Statements

News

There is no news available yet.